Beyond Air, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XAIR research report →
Range $10 – $10
Price Chart
About the company
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide.
- CEO
- Robert Goodman
- IPO
- 2018
- Employees
- 54
- HQ
- Garden City, NY, US
Get TickerSpark's AI analysis on XAIR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $977.34K
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.13
- P/B
- 0.65
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
- Gross Margin
- 9.96%
- Op Margin
- -321.65%
- Net Margin
- -407.31%
- ROE
- -619.10%
- ROIC
- -90.02%
Latest fiscal year · YoY change
- Revenue
- $7.68M+107.3%
- Gross Profit
- $252.00K+115.2%
- Op Income
- $-29,044,000
- Net Income
- $-33,249,000+28.7%
- EPS
- $-4.01+98.5%
- OCF Growth
- +52.5%
- FCF Growth
- +56.5%
- 52W High
- $53.20
- 52W Low
- $1.53
- 50D MA
- $2.45
- 200D MA
- $8.48
- Beta
- 0.15
- RSI (14)
- 29
- Avg Volume
- 228.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Beyond Air posted record quarterly revenue growth and improved gross margin, while management reiterated 2026 and 2027 revenue guidance and said FDA review of the second-generation LungFit PH is in its final stages.· November 11, 2026
- Quarterly revenue hit a record $2.3 million, up 28% year over year and 31% sequentially.
- Gross margin improved to 8% from negative 16% a year ago, and gross profit turned positive at $0.2 million.
- Management reaffirmed calendar 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, with second-generation LungFit PH expected to contribute in 2H27.
- The second-generation PMA supplement remains under FDA review; audit readiness is expected in mid-December, followed by inspection and final approval steps.
- Pipeline momentum was described as strong, with the U.S. pipeline close to fourfold from Q1 and win rates improving due to product acceptance and fewer competitors.
Revenue for the quarter was $2.3 million, compared with $1.8 million in the same period last year, up approximately 28% year over year and 31% from the June 2026 quarter. Gross margin was approximately 8%, versus negative 16% a year ago; gross profit was $0.2 million, versus a gross loss of $0.3 million last year. Net loss attributable to common stockholders was $7.8 million, or $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or $24.98 per basic and diluted share, in the prior-year quarter. Cash equivalents, restricted cash, and marketable securities totaled $18.5 million as of September 30, 2026, including $2.7 million held by Neuro-Israel, $0.7 million held by Beyond Cancer, and $4.8 million of restricted cash. Forward guidance was reaffirmed at $8 million of revenue for calendar 2026, excluding second-generation system revenue, and $16 million to $18 million for calendar 2027, including anticipated second-generation revenue pending FDA approval.
Robert Scott Goodman said the company is focused on commercial execution for LungFit PH while preparing for the potential launch of the second-generation system. He emphasized expanding market penetration, strengthening hospital relationships, and building recurring revenue through renewals and new account wins. His tone was constructive and confident, especially around the FDA timeline, the growing U.S. pipeline, and the belief that the second-generation product can broaden the market by adding transport capability.
Daniel Moorhead highlighted the quarter’s financial improvement and cost discipline. He pointed to revenue of $2.3 million, gross margin of 8%, R&D expense of $1.6 million versus $2.5 million last year, SG&A of $4.6 million versus $4.9 million, and other expense of $2.2 million versus $0.6 million, with the higher other expense tied mainly to interest expense and scrap material. He also noted the $18.5 million cash, restricted cash, and marketable securities balance at quarter-end and reminded investors that the company is changing its fiscal year end to December 31 effective December 31, 2026.
Analysts focused mainly on the FDA review path, asking whether anything beyond the planned audit remained and when approval might arrive. Management said the remaining process is essentially the audit and then FDA feedback, with audit readiness expected in mid-December and a response expected within a few weeks after the audit, though timing remains up to the FDA. Questions also covered why audit readiness took longer than earlier expected, and management said the timing reflected thorough repeatability and stability testing rather than a setback.
The call showed accelerating commercial traction, with record revenue, improved gross margin, and management saying the U.S. pipeline has grown close to fourfold from Q1. Management also pointed to strong receptivity to the product, higher win rates, and a second-generation system that could expand use in transport settings and support larger deals.
The biggest risk remains regulatory timing: the second-generation PMA supplement is still under FDA review, and the company cannot control when approval comes. The business is still small, the company reported a $7.8 million quarterly net loss, and management said it is not planning to devote resources to LungFit Go in 2027, while other subsidiaries are being monetized or partnered to keep focus on LungFit PH.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 110.8%
- Shares Outstanding
- 634.63K
- Float Shares
- 703.35K
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 103.00K | ▲ 103.00K |
| Balyasny Asset Management L.P. | 71.21K | ▼ 392.95K |
| Vanguard Group Inc | 60.44K | ▼ 43.97K |
| Northern Trust Corp | 17.05K | ▲ 17.05K |
| Hrt Financial LP | 12.67K | ▼ 8.43K |
| Bleichroeder LP | 4.33K | ▼ 82.16K |
| Vanguard Capital Management LLC | 3.14K | ▼ 59.60K |
| Vanguard Fiduciary Trust Co | 1.47K | ▼ 27.90K |
| Ubs Group AG | 1.28K | ▲ 1.27K |
| Tower Research Capital LLC (Trc) | 1.24K | ▼ 3.34K |
| Jones Financial Companies Lllp | 1.00K | ▲ 990 |
| Blackrock, Inc. | 933 | ▼ 21.10K |
Held by 7 ETFs
Biggest fund positions in XAIR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 13, 26 | Lin Yi-Chien | buy | 2,607 |
| Oct 1, 26 | Lin Yi-Chien | buy | 15,393 |
| Sep 30, 26 | Lin Yi-Chien | buy | 2,000 |
| Sep 29, 26 | Lin Yi-Chien | buy | 3,000 |
| Sep 28, 26 | Lin Yi-Chien | other | 0 |
| Jul 29, 26 | Goodman Robert Scott | buy | 34,722 |
| Jul 29, 26 | Goodman Robert Scott | buy | 34,722 |
| Jul 29, 26 | Goodman Robert Scott | buy | 34,722 |
| Jul 29, 26 | MOORHEAD DANIEL J | buy | 4,340 |
| Jul 29, 26 | MOORHEAD DANIEL J | buy | 4,340 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XAIR coverage
Recent articles, reports, and earnings notes.
No research on XAIR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XAIR report →Beyond Air, Inc. (XAIR) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 11
Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026
globenewswire.com · Nov 11
Max Hospitality Selects Beyond Oil as Frying Standard Across Its Restaurants and Venues
globenewswire.com · Nov 2
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
globenewswire.com · Oct 29
Beyond Oil Announces First Commercial Adoption in the Industrial Frying Segment
globenewswire.com · Oct 26
Beyond Oil Enters the Romanian Market with Initial Order from New Distributor
globenewswire.com · Oct 21
Duchess Restaurants Selects Beyond Oil as Frying Standard Across the Chain
globenewswire.com · Oct 19
Beyond Oil Appoints Joe Colligan as Chief Executive Officer of Beyond Oil USA
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.